SCHEMBL12952783

SCHEMBL12952783

CC(C)(C)c1ccc(Oc2cc(O)cc(-c3ccc(OC(F)(F)F)cc3)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.53
▸ TPX2 Q9ULW0 1/20 0.53
▸ TRPV1 Q8NER1 2/20 0.46
▸ EPHX2 P34913 1/20 0.43
▸ NR1H4 Q96RI1 1/20 0.43
▸ NPC1 O15118 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ SERPINE1 P05121 1/20 0.41
▸ AKR1C2 P52895 1/20 0.41
▸ AKR1C1 Q04828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21944789 0.83 AURKA (0.67) AURKATPX2EPHX2NPC1MAPK1
SCHEMBL13761670 0.82 TRPV1 (0.57) AURKATPX2TRPV1EPHX2NR1H4
SCHEMBL1690017 0.80 AURKA (0.71) AURKATPX2EPHX2NPC1MAPK1
SCHEMBL12952736 0.80 AURKA (0.71) AURKATPX2EPHX2NPC1MAPK1
SCHEMBL13580929 0.80 TRPV1 (0.45) AURKATPX2TRPV1EPHX2NR1H4
SCHEMBL13580812 0.80 TRPV1 (0.45) AURKATPX2TRPV1EPHX2NR1H4
SCHEMBL21944998 0.79 AURKA (0.54) AURKATPX2TRPV1NPC1MAPK1
SCHEMBL13580939 0.79 TRPV1 (0.47) TRPV1EPHX2NR1H4NPC1MAPK1
SCHEMBL5712237 0.78 MAPT (0.59) NPC1MAPK1RAB9AALDH1A1MAPT
SCHEMBL12732945 0.78 ALDH1A1 (0.59) NPC1MAPK1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 — — US disclosed
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 — — US disclosed
EP-2272817-A1 PAI-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2011-01-12 — — EP disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 — — US disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 — — US disclosed
WO-2009125606-A1 PAI-1 INHIBITOR 株式会社医薬分子設計研究所 (JP) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312315-A1 PAI-1 INHIBITOR SERPINC1, SERPINE1, SERPINH1 AURKA 3797/4885TPX2 1545/4885TRPV1 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback